Kidney disease research boosted with ‘shining example of collaboration’

Clinical trials to slow the progression of chronic kidney disease are set to be strengthened by a partnership between industry and the Scottish Government.

Health Secretary Neil Gray said the research aims to reduce the need for dialysis or kidney transplants.

It is the result of a partnership between NHS Scotland, AstraZeneca and Dundee and Glasgow universities.

Experts hope to develop new treatments, build infrastructure and enhance expertise in renal clinical trial delivery.

Preventing the disease’s progression may also protect patients from other consequences of the condition, such as heart failure, cardiovascular disease and stroke.

Mr Gray said: “This project’s ‘triple helix’ approach is a shining example of how collaboration between the NHS, Scottish Government, academia and industry can accelerate health studies.

“As we navigate the complex issue of chronic kidney disease, our commitment to patient-centred research remains unwavering.

“Together we can advance targeted studies into medicines that slow progression of the disease and reduce the need for dialysis or transplantation, strengthen our workforce through dedicated research fellows and specialised training, provide greater opportunities for patients, and enable Scotland to attract and deliver more innovative trials.”

Professor Dame Anna Dominiczak, chief scientist (health) at the Scottish Government, welcomed the partnership with AstraZeneca.

“We must all work together to improve the outcomes and life circumstances for people living with kidney disease, and this partnership enables the fusion of medical expertise, knowledge and insight from across NHS, academia and industry,” she said.

Tom Keith-Roach, UK president of AstraZeneca, said Scotland is setting a “bold ambition” to change the trajectory of chronic kidney disease.